|
|
Profile
|
Delegates :
Yosihhiro Oyamada |
|
Incorporated :
January 29 , 2019 |
Paid in Capital :
Million yen |
Employees :
人 |
Address :
Enoki-cho 33-94, Suita, OSAKA
〒5640053
|
TEL/FAX :
0663106036 / 0663106034 |
URL：
https://alphanavi.com/en/top/ |
Attachment :
|
Mission/Background :
AlphaNavi Pharma is developing a potent and selective voltage-gated sodium channel Nav1.7, Nav1.8, and Nav1.9 inhibitor, ANP-230, and a selective Nav1.7 inhibitor, ANP-390 for neuropathic pain, including Nav-mutated rare pain diseases. ANP-230 might be only one published clinical-stage compound which inhibit Nav1.9. In addition to it, both ANP-230 and ANP-390 have less CV- and CNS-related side effects, while it still has potent analgesic efficacy due to high peripheral Nav selectivity and quite low penetration rate to blood-brain barrier. We have completed several Phase 1 (UL, US, and Japan) and Phase 2 (Japn) studies for ANP-230 and a Phase 1 study (US) for ANP-390 and are now seeking the opportunities of out-licensing to expand the clinical development of ANP-230 and ANP-390 for neuropathic pain in US, EU and China. |
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
ANP-230
|
Phase1/2
|
It is a potent and selective inhibitor of Nav1.7, Nav1.8, and Nav1.9, possibly the only inhibitor of Nav1.9.
|
License out
|
ANP-231
|
Discovery
|
Transdermal formulation for ANP-230
|
Co-development
|
ANP-390
|
Phase1
|
ANP-390 is a potent and selective voltage-gated sodium channel Nav1.7 inhibitor.
|
License out
|
|
|
|
|
|
|
|
|
|
Highlights
|
【ANP-230】
Phase 1/2 study of ANP-230 to evaluate the safety, efficacy and pharmacokinetics in patients with Infantile episodic limb pain has completed in Japan.
There are two publications as below.
H. Okuda et al., Heliyon 9 (2023) e15423
T. Kamei et al., Biochemical and Biophysical Research Communications 721 (2024) 150126
【ANP-390】
Phase 1 SAD study of ANP-390 has completed in the US.
|
|
Alliance strategy
|
We are now seeking out-license opportunities for ANP-230 and ANP-390.
|
|
|